Showing 5121-5130 of 6036 results for "".
- Katena Products Acquires Micro-Select Instrumentshttps://modernod.com/news/katena-products-acquires-micro-select-instruments/2478435/Katena Products announced the purchase of Micro-Select Instruments, a maker of ophthalmic instruments including forceps, needle holders, and speculums. Terms of the deal were not disclosed. “The acquisition of Micro-Select is an important addition to Katena’s growing instrument manu
- Innovations Will Propel OCT Market to $549 Million in Revenue in 2020https://modernod.com/news/innovations-will-propel-oct-market-to-549-million-in-revenue-in-202/2478426/Recent innovations in optical coherence tomography (OCT) technology—such as systems that are combined with fundus imagers—and software advancements, including OCT angiography, are growing in popularity. At the same time promising new technologies on the horizon, such as at-home OCT devices, are g
- Blue Light Glasses Improve Sleep and Work Productivity, IU Research Showshttps://modernod.com/news/blue-light-glasses-improve-sleep-and-work-productivity-iu-research-shows/2478421/During the pandemic, the amount of screen time for many people working and learning from home as well as binge-watching TV has sharply increased. New research finds that wearing blue light glasses
- New World Medical Registers New KDB GLIDE for Smooth, Precise Goniotomyhttps://modernod.com/news/new-world-medical-registers-new-kdb-glide-for-smooth-precise-goniotomy/2478414/New World Medical announced FDA registration of the KDB GLIDE as a Class 1 device, designed to give surgeons a refined, precise experience performing excisional goniotomy for treatment of glaucoma. The KDB GLIDE device improves on the successful Kahook Dual Blade technology by adding new features
- Outlook Therapeutics Announces Initiation of Open-Label Safety Study of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-initiation-of-open-label-safety-study-for-lytenava-for-wet-amd/2478410/Outlook Therapeutics announced the initiation and enrollment of the first patients in its planned supplemental open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD) (NORSE THREE). The open-label safety study
- Hoya Surgical Optics Announces Global Launch of CLEARlog Apphttps://modernod.com/news/hoya-surgical-optics-announces-global-launch-of-clearlog-app/2478409/During the virtual ESCRS, the CLEARlog app was launched with the support of Hoya Surgical Optics. CLEARlog, which stands for “Cataract & Lens Exchange Analysis & Register” log, is an app that allows Cataract and Refractive Lens Exchange (RLE) surgeons to quickly and eff
- Santen Joins Forces With Ophthalmologists in the Fight Against Antibiotic Resistancehttps://modernod.com/news/santen-joins-forces-with-ophthalmologists-in-the-fight-against-antibiotic-resistance/2478406/Santen announced the launch of the Re-SOLVE Antibiotic Resistance initiative, which aims to lead the way in the fight against antibiotic resistance in ophthalmology. The initiative will promote and encourage good antibiotic stewardship—a set of actions for the sustainable and effective use of ant
- Bausch Health Licenses Eyenovia’s Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12https://modernod.com/news/bausch-health-licenses-eyenovias-investigational-treatment-for-the-reduction-of-pediatric-myopia-progression-in-children-ages-3-12/2478405/Bausch Health Companies and Eyenovia announced that an affiliate of Bausch Health has acquired an exclusive license in the United States and Canada for the development and commercialization of an investigational microdose formulati
- EyeCare4Kids Partners with 1-800 Contacts to Launch Sight the Worldhttps://modernod.com/news/eyecare4kids-partners-with-1-800-contacts-to-launch-sight-the-world/2478400/1-800 Contacts and nonprofit EyeCare4Kids announced the launch of Sight the World, which will utilize innovative vision care technology from 1-800 Contacts to provide free glasses and contact lenses for underserved adults and children globally. The announcement comes on World Sight Day, an intern
- Lilly, Incyte’s Olumiant Shows “Significant Effect” on COVID-19 Recovery Timeshttps://modernod.com/news/lilly-incytes-olumiant-shows-significant-effect-on-covid-19-recovery-times/2478401/Eli Lilly and Incyte shared more details, including mortality data, from the ongoing ACTT 2 trial evaluating their JAK1/JAK2 inhibitor Olumiant (baricitinib) in combination with Gilead Sciences’ Veklury (remdesivir) in patients with COVID-19 infection. The companies said last month that the